Vertex Pharmaceuticals Balance Sheet
NASDAQ: VRTXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vertex Pharmaceuticals financial position
At the end of fiscal 2025, Vertex Pharmaceuticals reported total assets of $25.64 billion, up 13.8% from a year earlier against total liabilities of $6.98 billion. Shareholders' equity stood at $18.67 billion, or 72.8% of assets. The company held $5.08 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.90, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vertex Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 5.08B | 4.57B | 10.37B | 10.50B | 6.79B | 5.99B | 3.11B | 2.65B | 1.67B | 1.18B |
| Short-Term Investments | 1.52B | 1.55B | 849.20M | 274.50M | 729.90M | 670.70M | 698.97M | 518.11M | 423.25M | 250.61M |
| Receivables | 2.05B | 1.61B | 1.56B | 1.44B | 1.14B | 885.40M | 633.52M | 409.69M | 281.34M | 200.36M |
| Inventory | 1.69B | 1.21B | 738.80M | 460.60M | 353.10M | 280.80M | 167.50M | 124.36M | 111.83M | 77.60M |
| Total Current Assets | 11.20B | 9.60B | 14.14B | 13.23B | 9.56B | 8.13B | 4.82B | 3.84B | 2.65B | 1.83B |
| Property, Plant & Equipment | 1.52B | 1.23B | 1.16B | 1.11B | 1.09B | 958.50M | 745.08M | 812.00M | 789.44M | 698.36M |
| Goodwill | 1.09B | 1.09B | 1.09B | 1.09B | 1.00B | 1.00B | 1.00B | 50.38M | 50.38M | 50.38M |
| Intangible Assets | 424.20M | 825.90M | 839.90M | 603.60M | 400.00M | 400.00M | 400.00M | 0 | — | — |
| Long-Term Investments | 5.71B | 5.11B | 2.50B | 112.20M | — | — | — | — | — | — |
| Total Assets | 25.64B | 22.53B | 22.73B | 18.15B | 13.43B | 11.75B | 8.32B | 6.25B | 3.55B | 2.90B |
| Accounts Payable | 461.70M | 413.00M | 364.90M | 303.90M | 195.00M | 155.10M | 87.61M | 110.99M | 73.99M | 61.45M |
| Total Current Liabilities | 3.86B | 3.56B | 3.55B | 2.74B | 2.14B | 1.88B | 1.33B | 1.12B | 807.26M | 792.54M |
| Long-Term Debt | — | — | — | — | — | — | — | — | — | 0 |
| Total Liabilities | 6.98B | 6.12B | 5.15B | 4.24B | 3.33B | 3.06B | 2.23B | 1.81B | 1.50B | 1.56B |
| Shareholders' Equity | 18.67B | 16.41B | 17.58B | 13.91B | 10.10B | 8.69B | 6.09B | 4.44B | 2.03B | 1.16B |
| Retained Earnings | 13.56B | 9.61B | 10.14B | 6.52B | 3.20B | 858.70M | -1.85B | -2.99B | -5.12B | -5.37B |
| Total Debt | — | — | — | — | — | — | — | — | — | 0 |
| Net Cash (Debt) | 6.61B | 6.12B | 11.22B | 10.78B | 7.52B | 6.66B | 3.81B | 3.17B | 2.09B | 1.43B |
| Shares Outstanding | 253.99M | 256.94M | 257.70M | 257.01M | 254.48M | 259.89M | 258.99M | 255.17M | 253.25M | 248.30M |
This table shows 10 annual periods of Vertex Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow VRTX's reporting calendar. What is a balance sheet?